Retina:非对称性糖尿病视网膜病变在视轴异位患者中的研究进展

2018-03-18 cuiguizhong MedSci原创

韩国清州忠北国立大学医学院眼科的Kim DY近日在Retina发表了一项文章,探讨糖尿病视网膜病变(DR)在双眼轴性屈光参差患者间的发展差异。

韩国清州忠北国立大学医学院眼科的Kim DY近日在Retina发表了一项文章,探讨糖尿病视网膜病变(DR)在双眼轴性屈光参差患者间的发展差异。

他们对糖尿病患者每只眼睛具有不同轴向长度(差异大于1mm)进行回顾性研究。使用早期治疗糖尿病视网膜病变研究DR分级系统,对通过荧光素血管造影术和早期治疗糖尿病视网膜病变的眼底照片进行分级。此外,根据轴向长度和眼窝下部脉络膜厚度分析糖尿病视网膜病变的严重程度。

经过严格筛选,总共纳入了6,963例DR患者中的34例。平均年龄为53.53±12.20岁,糖尿病病程为9.63±7.73年。眼睛长、短平均轴长分别为26.21±2.04mm和23.21±1.73mm(P <0.001)。在较短的眼睛中,61.7%(34/21)的眼睛有增生性糖尿病视网膜病变。与视轴较短的眼睛相比,较长的眼睛中仅8眼(34眼中的8眼,23.5%)具有增殖性糖尿病视网膜病变(McNemar test,P <0.001)。在眼窝下部脉络膜厚度较薄(<250μm)的眼睛中,增殖性糖尿病视网膜病变比率显着降低(P = 0.007)。

因此,他们认为,患有轴性屈光参差的患者中,视轴较长的眼睛比较短的眼睛具有较低的糖尿病视网膜病变(DR)风险。这一结果表明,轴长的伸长对DR的发展具有保护作用。

原文出处:

Kim, D.Y., et al., ASYMMETRIC DIABETIC RETINOPATHY PROGRESSION IN PATIENTS WITH AXIAL ANISOMETROPIA. Retina, 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1913864, encodeId=a9de1913864ca, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Aug 17 01:01:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793305, encodeId=fdb61e9330576, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Wed Jul 04 00:01:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270023, encodeId=d25a12e002339, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Mar 20 07:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380959, encodeId=a921138095928, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Tue Mar 20 07:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413934, encodeId=0aa61413934e2, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue Mar 20 07:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=)]
    2018-08-17 ysjykql
  2. [GetPortalCommentsPageByObjectIdResponse(id=1913864, encodeId=a9de1913864ca, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Aug 17 01:01:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793305, encodeId=fdb61e9330576, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Wed Jul 04 00:01:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270023, encodeId=d25a12e002339, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Mar 20 07:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380959, encodeId=a921138095928, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Tue Mar 20 07:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413934, encodeId=0aa61413934e2, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue Mar 20 07:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1913864, encodeId=a9de1913864ca, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Aug 17 01:01:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793305, encodeId=fdb61e9330576, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Wed Jul 04 00:01:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270023, encodeId=d25a12e002339, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Mar 20 07:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380959, encodeId=a921138095928, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Tue Mar 20 07:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413934, encodeId=0aa61413934e2, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue Mar 20 07:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=)]
    2018-03-20 zutt
  4. [GetPortalCommentsPageByObjectIdResponse(id=1913864, encodeId=a9de1913864ca, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Aug 17 01:01:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793305, encodeId=fdb61e9330576, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Wed Jul 04 00:01:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270023, encodeId=d25a12e002339, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Mar 20 07:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380959, encodeId=a921138095928, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Tue Mar 20 07:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413934, encodeId=0aa61413934e2, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue Mar 20 07:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1913864, encodeId=a9de1913864ca, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Aug 17 01:01:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793305, encodeId=fdb61e9330576, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Wed Jul 04 00:01:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270023, encodeId=d25a12e002339, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Mar 20 07:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380959, encodeId=a921138095928, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Tue Mar 20 07:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413934, encodeId=0aa61413934e2, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue Mar 20 07:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=)]

相关资讯

Am J Med Sci:中国人中骨质代谢标志物与糖尿病视网膜病变和糖尿病性黄斑水肿之间的相关性研究!

中国医学科学院北京协和医科大学眼科系的Zhang X近日在Am J Med Sci杂志上发表了他们近期的一项工作,他们对骨质代谢标志物与糖尿病视网膜病变和糖尿病性黄斑水肿之间的关联进行了研究。

Microvasc Res:健康和糖尿病视网膜病变受试者中结膜微血管血流动力学测量的时间变化!

美国加利福尼亚州南加州大学眼科学系的Khansari MM近日在Microvasc Res杂志上发表了一项重要工作。结膜微循环成像是一种非侵入性技术,可以用于检测由全身和眼部疾病引起的血液动力学变化。然而,由于疾病发展引起的血流动力学变化监测需要纵向检测,即记录随时间变化的测量。本研究的目的是确定非糖尿病对照组(NC,N = 7)和糖尿病视网膜病变(DR,N = 10)受试者中结膜微血管血流动力学

Br J Ophthalmol:糖尿病视网膜病变的早期指标-视网膜动脉壁厚度

糖尿病视网膜病变(DR)是一种致盲率很高的疾病,而且该类患者正在逐渐增多。为了预防糖尿病的这种微血管并发症,很多学会提出了不少预防措施,包括控制血糖、糖化血红蛋白以及血压等。一般来说,DR是一种高血糖导致的新陈代谢紊乱的病变,会增加血管基底膜成分的合成和积累,并导致基底膜的增厚。但是这些早期的变化并不能被我们常规的眼底检查发现,如果我们能在DR出现临床症状前通过直接可视化和非侵入性的手段来及早发现

Telemed J E Health. :患者家庭开车到眼科医生办公室的时间对糖尿病视网膜病变筛查的影响!

法国马赛大学的Macon C近日在Telemed J E Health杂志上发表了他们的一项很有趣的工作,他们研究了开汽车到最近眼科医生的时间对筛查糖尿病视网膜病变(DR)的影响,他们发现,距离最近眼科医生开车时间越长,糖尿病患者筛查出患糖尿病视网膜病变(DR)的时间也越长。

我国糖尿病视网膜病变筛查的图像采集及阅片指南(2017年)

2014年中华医学会眼科学分会眼底病学组撰写的《我国糖尿病视网膜病变临床诊疗指南(2014年)》作为第1版国人DR筛查、诊断和干预指南,对全科医师、眼科专科医师和眼底病专业医师的DR临床诊疗工作发挥了重要的指导作用。目前我国87%糖尿病患者就诊于眼科医疗资源极其有限的县级及以下医疗机构。部分DR流行病学调查结果显示,50%以上就诊于基层医疗机构的糖尿病患者未被告知应定期进行眼底检查,近70%糖尿病

Invest Ophthalmol Vis Sci:市售的扫描激光眼镜在糖尿病视网膜病变的应用--视网膜血氧饱和度和血管直径测量!

美国伊利诺伊大学眼科与视觉科学系的Blair NP近日在Invest Ophthalmol Vis Sci杂志上发表了他们近期的一项工作,他们用市售的扫描激光检眼镜(SLO)来辨别不同糖尿病性视网膜病变(DR)阶段的视网膜血管直径和血红蛋白氧饱和度的变化。